A carregar...
miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase
BACKGROUND: Currently, O6-methylguanine-DNA methyltransferase(MGMT) promoter methylation is the most convincing predictive biomarker for temozolomide (TMZ) response in patients with glioblastoma multiforme (GBM). However, technical obstacles prevent this biomarker from being applied widely. On the o...
Na minha lista:
| Publicado no: | J Transl Med |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4345002/ https://ncbi.nlm.nih.gov/pubmed/25890369 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0435-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|